Oncoinvent ASA Cancels Subsequent Repair Offering
Oncoinvent ASA has decided to cancel its planned subsequent repair offering. The company previously announced a successful share issue and its intention to offer up to 200,000 new shares.
Oncoinvent ASA has announced the cancellation of its planned subsequent repair offering. The company had previously completed a successful private placement and a retail offering, issuing a total of 1,650,000 new shares at a subscription price of NOK 90 per share.
Originally, the company had intended to conduct a subsequent repair offering of up to 200,000 new shares. The specific reasons for the cancellation of this offering have not been further detailed in the public announcement.
Oncoinvent is a biotechnology company focused on cancer therapies, particularly in the development of new treatment modalities using radiopharmaceuticals. The company aims to advance cancer patient care through the development of novel and effective solutions.
The funds raised from the initial share issue were intended to support the company's research and development activities and general corporate purposes. However, the cancellation of the repair offering may impact the company's financing structure and future development plans.